Stifel analysts reiterated their Buy rating for Arcellx Inc. (NASDAQ: ACLX) with a consistent price target of $122.00. Currently trading at $64.01, the stock has significant upside potential according ...

Please watch the video at Investors.com - How To Buy Stocks: IBD's Four Pillars Of Investing On Sunday, Arcellx said 97% of patients responded to treatment with its CAR-T drug, anito-cel ...

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma, with a 97% response rate and low neurotoxicity, potentially differentiating it in a crowded market. Financially robust ...

On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...